Avience Biomedicals IPO
Healthcare • ₹30.24 Cr
High risk because:
- 5 material risk factors disclosed in DRHP
- High customer concentration flagged in the DRHP
- Working capital or debt pressure highlighted in DRHP
IPOFins risk score from DRHP risk factors, subscription demand & issue structure
Price Band
₹208
Lot Size
600 shares
Issue Size
₹30.24 Cr
Open
18 Jun 2026
Close
22 Jun 2026
Subscription
353×
IPO Schedule
| Issue Open Date | 18 Jun 2026 |
| Issue Close Date | 22 Jun 2026 |
| Listing Date | 24 Jun 2026 |
About Avience Biomedicals
Avience Biomedicals Limited is a medical consumables company that manufactures in vitro diagnostic (IVD) products and medical devices. The company’s product portfolio includes diagnostic kits for diseases such as COVID-19, HIV, malaria, dengue, and HBsAg, as well as serology products, biochemistry analysers, biochemistry reagents, culture media, and other medical consumables. In addition to manufacturing, the company also operates as a distributor and trader of medical equipment. Its products are supplied to pathology laboratories, microbiology laboratories, hospitals, research centres, government organisations, and distributors across India, and some exports too. Avience Biomedicals operates its manufacturing facility in Noida, Uttar Pradesh. This unit is equipped for the production of diagnostic kits, reagents, analysers, and related healthcare products. The company also has its registered office in New Delhi and has been allotted land in the Medical Device Park in the Yamuna Expressway Industrial Development Area, Uttar Pradesh.
Company Details
Founders / Promoters
Mr Dharam Deo Choudhary
Founded
2019
Registrar
SKYLINE
Documents
DRHP / RHP Document (PDF)
View official prospectus →
Investment Analysis
Avience Biomedicals — IPOFins Verdict
QuantitativeDriven by QIB demand at 196.8x and elevated disclosed risk (7/10), Avience Biomedicals listed at a premium of 90.0% to its issue price. SME listings are also thinner and more volatile after listing. The signals lean constructive — still confirm valuation against listed peers and read the DRHP before applying beyond one lot.
- The company claims to have a diversified portfolio of in-vitro diagnostic (IVD) products and medical devices. Its offerings include rapid diagnostic test kits for infectious diseases, serology product
- The company is ISO:13485 certified for medical device quality management systems and ISO:9001 certified for quality management systems. It also claims that its products comply with CE standards and Go
- The company operates both as a manufacturer of diagnostic products and a distributor and trader of medical equipment. In addition, it is a channel partner for Mindray, allowing it to offer biochemistr
- The company claims to have an in-house team of service engineers that provides installation, training, and maintenance support for medical equipment. This allows it to offer post-sales technical suppo
- The company has established a manufacturing facility in Noida, Uttar Pradesh, and has also been allotted industrial land in the Medical Device Park at YEIDA. The proposed facility within the medical d
Score breakdown — what drove this verdict
High risk from DRHP → score -0.8
Institutional subscription → score +2.0
Strong retail interest → score +0.5
Actual listing outcome → score +1.5
SME IPOs have lower liquidity after listing → score −0.5
Base score: 5.0 · Final score = base + all factor adjustments, capped 1–10. Full methodology →
IPOFins Score is a quantitative signal from subscription demand, disclosed risk, and listing data — not investment advice. Not SEBI-registered.
Listing Performance
Issue Price
₹208
Listing Price
₹395.2
Listing Gain/Loss
+90.00%
Listing Date
24 Jun 2026
Price Since Listing
Returns are measured against the ₹208 issue price.
Listing
₹395.2
+90.0%
Current
₹247
+18.8%
Want to buy this stock?
Trade Avience Biomedicals on the secondary market
FAQ
What is the price band of Avience Biomedicals IPO?
The price band is ₹208 per share with a lot size of 600 shares. Minimum investment: ₹1,24,800.
What does Avience Biomedicals do?
Avience Biomedicals Limited is a medical consumables company that manufactures in vitro diagnostic (IVD) products and medical devices. The company’s product portfolio includes diagnostic kits for diseases such as COVID-19, HIV, malaria, dengue, and HBsAg, as well as serology products, biochemistry analysers, biochemistry reagents, culture media, and other medical consumables. In addition to manufacturing, the company also operates as a distributor and trader of medical equipment. Its products are supplied to pathology laboratories, microbiology laboratories, hospitals, research centres, government organisations, and distributors across India, and some exports too. Avience Biomedicals operates its manufacturing facility in Noida, Uttar Pradesh. This unit is equipped for the production of diagnostic kits, reagents, analysers, and related healthcare products. The company also has its registered office in New Delhi and has been allotted land in the Medical Device Park in the Yamuna Expressway Industrial Development Area, Uttar Pradesh.
Should I apply for Avience Biomedicals IPO?
Avience Biomedicals listed at ₹395.2 (+90.0% premium to the ₹208 issue price) after 353.0x subscription. IPOFins Score 8/10: Driven by QIB demand at 196.8x and elevated disclosed risk (7/10), Avience Biomedicals listed at a premium of 90.0% to its issue price. SME listings are also thinner and more volatile after listing. The signals lean constructive — still confirm valuation against listed peers and read the DRHP before applying beyond one lot.
Who founded Avience Biomedicals?
Avience Biomedicals was founded by Mr Dharam Deo Choudhary in 2019.